Enzyme structure found in Mycobacterium tuberculosis (Mtb), the bacterium that causes tuberculosis (TB) by scientists at the University of Warwick may help develop new therapies to eradicate tuberculosis.

TOP INSIGHT
An enzyme found in Mycobacterium tuberculosis (Mtb), the bacterium that causes tuberculosis (TB), may be a new target for future tuberculosis therapies.
The team found a key structural motif in the tuberculosis N-acetylglucosamine-6-phosphate deacetylase (NagA) enzyme. Attacking this structural motif through the design and exploitation of new molecules will enable scientists to inhibit this critical pathway and kill TB.
Using the X-ray facilities at the Diamond Light Source, Harwell, they were provided with detailed molecular insights into how the NagA enzyme generates important precursors that are involved in Mtb cell wall biosynthesis and metabolism.
Dr Fullam, who is a Sir Henry Dale Fellow at the University of Warwick's School of Life Sciences, said: "Tuberculosis is a major global health problem and the current drugs that we use today are over 40 years old. It is therefore vital that we discover new therapeutic agents to combat TB. In our studies, we have investigated the role of an enzyme in Mtb called NagA. This enzyme is a promising drug target as it is at a crucial metabolic chokepoint in Mtb. This means that a molecule that stops the enzyme from working would be an effective strategy for a drug and therefore it is critical to understand its function.
"Our group has identified a weak point within this protein that we can target and will now enable us to design specific molecules to block its function"
The research is published in the Journal of Biological Chemistry.
MEDINDIA




Email










